{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:56:42Z","timestamp":1786982202117,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shenzhen Major Scientific and Technological Project.","award":["KJZD20230923115110020"],"award-info":[{"award-number":["KJZD20230923115110020"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-025-01368-9","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T10:22:17Z","timestamp":1768904537000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Synergistic Effect of Fecal Microbiota Transplantation, \u03b3\u03b4T Cell Immunotherapy, and Pembrolizumab in Refractory Advanced Pancreatic Cancer: A Case Report"],"prefix":"10.1007","volume":"57","author":[{"given":"Mohammed","family":"Alnaggar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongshun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuimin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengzhou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonggan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuad A.","family":"Abdu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"issue":"9","key":"1368_CR1","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.62347\/AVYM3477","volume":"14","author":"Y Tang","year":"2024","unstructured":"Tang Y, et al. ZIP4: a promising early diagnostic and therapeutic targets for pancreatic cancer. Am J Cancer Res. 2024;14(9):4652\u201364.","journal-title":"Am J Cancer Res"},{"key":"1368_CR2","doi-asserted-by":"publisher","first-page":"1481247","DOI":"10.3389\/fimmu.2024.1481247","volume":"15","author":"Q Wang","year":"2024","unstructured":"Wang Q, et al. Targeting the CSF1\/CSF1R signaling pathway: an innovative strategy for ultrasound combined with macrophage exhaustion in pancreatic cancer therapy. Front Immunol. 2024;15:1481247.","journal-title":"Front Immunol"},{"key":"1368_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cells10020444","author":"M Ammendola","year":"2021","unstructured":"Ammendola M, et al. Mast cells positive for c-Kit receptor and tryptase correlate with angiogenesis in cancerous and adjacent normal pancreatic tissue. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10020444.","journal-title":"Cells"},{"issue":"22","key":"1368_CR4","first-page":"6862","volume":"25","author":"C Laface","year":"2021","unstructured":"Laface C, et al. Chymase-positive mast cells correlate with tumor angiogenesis: first report in pancreatic cancer patients. Eur Rev Med Pharmacol Sci. 2021;25(22):6862\u201373.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1368_CR5","doi-asserted-by":"publisher","first-page":"1469096","DOI":"10.3389\/fimmu.2024.1469096","volume":"15","author":"X Zhong","year":"2024","unstructured":"Zhong X, et al. Effects and mechanisms of Helicobacter pylori on cancers development and immunotherapy. Front Immunol. 2024;15:1469096.","journal-title":"Front Immunol"},{"issue":"3","key":"1368_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/CAD.0000000000001546","volume":"35","author":"L Qiu","year":"2024","unstructured":"Qiu L, Liu C, Li H. Successful immunotherapy with PD-1 iinhibitor for advanced pancreatic cancer: report of two cases and review of literature. Anticancer Drugs. 2024;35(3):263\u201370.","journal-title":"Anticancer Drugs"},{"key":"1368_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176451","volume":"969","author":"PC Balar","year":"2024","unstructured":"Balar PC, Apostolopoulos V, Chavda VP. A new era of immune therapeutics for pancreatic cancer: monoclonal antibodies paving the way. Eur J Pharmacol. 2024;969:176451.","journal-title":"Eur J Pharmacol"},{"key":"1368_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-025-03414-z","author":"W Zhang","year":"2025","unstructured":"Zhang W, et al. CLDN18.2-targeting STAR-T cell therapy for pancreatic cancer: a strategy to minimize gastric off-tumor toxicity compared to CLDN18.2 CAR-T. Oncogene. 2025. https:\/\/doi.org\/10.1038\/s41388-025-03414-z.","journal-title":"Oncogene"},{"issue":"1","key":"1368_CR9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/jso.24627","volume":"116","author":"CJ DeSelm","year":"2017","unstructured":"DeSelm CJ, et al. CAR T-cell therapy for pancreatic cancer. J Surg Oncol. 2017;116(1):63\u201374.","journal-title":"J Surg Oncol"},{"issue":"5","key":"1368_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/08830185.2020.1776274","volume":"39","author":"M Sahlolbei","year":"2020","unstructured":"Sahlolbei M, et al. Evaluation of targetable biomarkers for chimeric antigen receptor T-cell (CAR-T) in the treatment of pancreatic cancer: a systematic review and meta-analysis of preclinical studies. Int Rev Immunol. 2020;39(5):223\u201332.","journal-title":"Int Rev Immunol"},{"key":"1368_CR11","doi-asserted-by":"publisher","first-page":"1466266","DOI":"10.3389\/fimmu.2024.1466266","volume":"15","author":"D Zhu","year":"2024","unstructured":"Zhu D, et al. Potential of gamma\/delta T cells for solid tumor immunotherapy. Front Immunol. 2024;15:1466266.","journal-title":"Front Immunol"},{"key":"1368_CR12","doi-asserted-by":"publisher","first-page":"108895","DOI":"10.1016\/j.intimp.2022.108895","volume":"108","author":"F Nezhad Shamohammadi","year":"2022","unstructured":"Nezhad Shamohammadi F, et al. Controversial role of gammadelta T cells in pancreatic cancer. Int Immunopharmacol. 2022;108:108895.","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"1368_CR13","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1080\/17474124.2017.1312344","volume":"11","author":"D Daley","year":"2017","unstructured":"Daley D, Miller G. The role of gammadelta T cells in pancreatic cancer: what could this mean for the clinic? Expert Rev Gastroenterol Hepatol. 2017;11(7):609\u201310.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"1368_CR14","doi-asserted-by":"publisher","first-page":"1524899","DOI":"10.3389\/fimmu.2025.1524899","volume":"16","author":"Y Zhu","year":"2025","unstructured":"Zhu Y, et al. Efficacy of natural killer T and gammadelta T cells in mesothelin-targeted immunotherapy of pancreatic cancer. Front Immunol. 2025;16:1524899.","journal-title":"Front Immunol"},{"issue":"1","key":"1368_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40425-019-0501-8","volume":"7","author":"M Alnaggar","year":"2019","unstructured":"Alnaggar M, et al. Allogenic Vgamma9Vdelta2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma. J Immunother Cancer. 2019;7(1):36.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1368_CR16","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12985-020-01449-0","volume":"17","author":"A Sabbaghi","year":"2020","unstructured":"Sabbaghi A, et al. Role of gammadelta T cells in controlling viral infections with a focus on influenza virus: implications for designing novel therapeutic approaches. Virol J. 2020;17(1):174.","journal-title":"Virol J"},{"issue":"4","key":"1368_CR17","first-page":"291","volume":"3","author":"L Guo","year":"2006","unstructured":"Guo L, et al. Response to hepatocarcinoma Hca-F of mice immunized with heat shock protein 70 from elemene combo tumor cell vaccine. Cell Mol Immunol. 2006;3(4):291\u20135.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"1368_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12866-023-03166-4","volume":"24","author":"G Pourali","year":"2024","unstructured":"Pourali G, et al. Microbiome as a biomarker and therapeutic target in pancreatic cancer. BMC Microbiol. 2024;24(1):16.","journal-title":"BMC Microbiol"},{"issue":"1","key":"1368_CR19","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2025.2470372","volume":"17","author":"Y Liang","year":"2025","unstructured":"Liang Y, et al. Upregulation of Lactobacillus spp. in gut microbiota as a novel mechanism for environmental eustress-induced anti-pancreatic cancer effects. Gut Microbes. 2025;17(1):2470372.","journal-title":"Gut Microbes"},{"issue":"8","key":"1368_CR20","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/s41591-023-02453-x","volume":"29","author":"B Routy","year":"2023","unstructured":"Routy B, et al. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. Nat Med. 2023;29(8):2121\u201332.","journal-title":"Nat Med"},{"issue":"6529","key":"1368_CR21","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1126\/science.abb5920","volume":"371","author":"EN Baruch","year":"2021","unstructured":"Baruch EN, et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2021;371(6529):602\u20139.","journal-title":"Science"},{"issue":"1","key":"1368_CR22","doi-asserted-by":"publisher","first-page":"2452277","DOI":"10.1080\/19490976.2025.2452277","volume":"17","author":"A Lin","year":"2025","unstructured":"Lin A, et al. From chaos to order: optimizing fecal microbiota transplantation for enhanced immune checkpoint inhibitors efficacy. Gut Microbes. 2025;17(1):2452277.","journal-title":"Gut Microbes"},{"issue":"10","key":"1368_CR23","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41571-023-00803-9","volume":"20","author":"RC Simpson","year":"2023","unstructured":"Simpson RC, et al. Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2023;20(10):697\u2013715.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"1368_CR24","doi-asserted-by":"publisher","first-page":"G711","DOI":"10.1152\/ajpgi.00171.2024","volume":"327","author":"MS Bohm","year":"2024","unstructured":"Bohm MS, et al. Fecal microbial transplants as investigative tools in cancer. Am J Physiol Gastrointest Liver Physiol. 2024;327(5):G711\u201326.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"1368_CR25","doi-asserted-by":"crossref","unstructured":"Mohamed AA, Al-Ramadi BK, Fernandez-Cabezudo MJ. Interplay between microbiota and gammadelta T cells: insights into immune homeostasis and Neuro-Immune interactions. Int J Mol Sci, 2024. 25(3).","DOI":"10.3390\/ijms25031747"},{"issue":"5","key":"1368_CR26","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s00262-022-03329-8","volume":"72","author":"M Ninkov","year":"2023","unstructured":"Ninkov M, et al. Improved MAIT cell functions following fecal microbiota transplantation for metastatic renal cell carcinoma. Cancer Immunol Immunother. 2023;72(5):1247\u201360.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"1368_CR27","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41392-020-00260-1","volume":"5","author":"M Lin","year":"2020","unstructured":"Lin M, et al. Irreversible electroporation plus allogenic Vgamma9Vdelta2 T cells enhances antitumor effect for locally advanced pancreatic cancer patients. Signal Transduct Target Ther. 2020;5(1):215.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1368_CR28","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/s41467-024-45449-y","volume":"15","author":"SC Lien","year":"2024","unstructured":"Lien SC, et al. Tumor reactive gammadelta T cells contribute to a complete response to PD-1 Blockade in a Merkel cell carcinoma patient. Nat Commun. 2024;15(1):1094.","journal-title":"Nat Commun"},{"issue":"1","key":"1368_CR29","doi-asserted-by":"publisher","first-page":"1989789","DOI":"10.1080\/2162402X.2021.1989789","volume":"10","author":"MH Nada","year":"2021","unstructured":"Nada MH, et al. PD-1 checkpoint Blockade enhances adoptive immunotherapy by human Vgamma2Vdelta2 T cells against human prostate cancer. Oncoimmunology. 2021;10(1):1989789.","journal-title":"Oncoimmunology"},{"issue":"1","key":"1368_CR30","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12876-023-02853-w","volume":"23","author":"F Petrelli","year":"2023","unstructured":"Petrelli F, et al. Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis. BMC Gastroenterol. 2023;23(1):212.","journal-title":"BMC Gastroenterol"},{"issue":"10","key":"1368_CR31","first-page":"004767","volume":"11","author":"A Singh","year":"2024","unstructured":"Singh A, et al. Pembrolizumab in combination with Folfirinox for treatment of advanced pancreatic adenocarcinoma with MSI-H. Eur J Case Rep Intern Med. 2024;11(10):004767.","journal-title":"Eur J Case Rep Intern Med"},{"issue":"8","key":"1368_CR32","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s12032-023-02101-x","volume":"40","author":"M El-Tanani","year":"2023","unstructured":"El-Tanani M, et al. Impact of exosome therapy on pancreatic cancer and its progression. Med Oncol. 2023;40(8):225.","journal-title":"Med Oncol"},{"issue":"18","key":"1368_CR33","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.1158\/1078-0432.CCR-21-0929","volume":"27","author":"B Bockorny","year":"2021","unstructured":"Bockorny B, et al. Motixafortide and pembrolizumab combined to nanoliposomal Irinotecan, Fluorouracil, and folinic acid in metastatic pancreatic cancer: the COMBAT\/KEYNOTE-202 trial. Clin Cancer Res. 2021;27(18):5020\u20137.","journal-title":"Clin Cancer Res"},{"issue":"10302","key":"1368_CR34","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun JM, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759\u201371.","journal-title":"Lancet"},{"issue":"4","key":"1368_CR35","doi-asserted-by":"publisher","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","volume":"19","author":"MA Tempero","year":"2021","unstructured":"Tempero MA, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(4):439\u201357.","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"1368_CR36","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1093\/oncolo\/oyad044","volume":"28","author":"F Crowley","year":"2023","unstructured":"Crowley F, et al. Adherence to NCCN genetic testing guidelines in pancreatic cancer and impact on treatment. Oncologist. 2023;28(6):486\u201393.","journal-title":"Oncologist"},{"issue":"2","key":"1368_CR37","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41423-020-0515-7","volume":"18","author":"Y Xu","year":"2021","unstructured":"Xu Y, et al. Allogeneic Vgamma9Vdelta2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer. Cell Mol Immunol. 2021;18(2):427\u201339.","journal-title":"Cell Mol Immunol"},{"issue":"6717","key":"1368_CR38","doi-asserted-by":"publisher","first-page":"eabq7248","DOI":"10.1126\/science.abq7248","volume":"386","author":"A Hayday","year":"2024","unstructured":"Hayday A, et al. Cancer immunotherapy by gammadelta T cells. Science. 2024;386(6717):eabq7248.","journal-title":"Science"},{"key":"1368_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15123143","author":"V Papa","year":"2023","unstructured":"Papa V, et al. The role of microbiota in pancreatic cancer. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15123143.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"1368_CR40","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1136\/gutjnl-2019-319807","volume":"70","author":"V Chandra","year":"2021","unstructured":"Chandra V, McAllister F. Therapeutic potential of microbial modulation in pancreatic cancer. Gut. 2021;70(8):1419\u201325.","journal-title":"Gut"},{"key":"1368_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14090861","author":"A Boicean","year":"2024","unstructured":"Boicean A, et al. The importance of microbiota and fecal microbiota transplantation in pancreatic disorders. Diagnostics (Basel). 2024. https:\/\/doi.org\/10.3390\/diagnostics14090861.","journal-title":"Diagnostics (Basel)"},{"issue":"9","key":"1368_CR42","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1038\/s12276-023-00985-3","volume":"55","author":"I Kang","year":"2023","unstructured":"Kang I, Kim Y, Lee HK. Double-edged sword: gammadelta T cells in mucosal homeostasis and disease. Exp Mol Med. 2023;55(9):1895\u2013904.","journal-title":"Exp Mol Med"},{"key":"1368_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111659","author":"V Martini","year":"2019","unstructured":"Martini V, et al. Circulating tumor cells in pancreatic cancer: current perspectives. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11111659.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"1368_CR44","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2022.2559","volume":"17","author":"E Ermiah","year":"2022","unstructured":"Ermiah E, et al. Prognostic value of serum CEA and CA19-9 levels in pancreatic ductal adenocarcinoma. Mol Clin Oncol. 2022;17(2):126.","journal-title":"Mol Clin Oncol"},{"issue":"1","key":"1368_CR45","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12876-017-0709-3","volume":"17","author":"AK Berger","year":"2017","unstructured":"Berger AK, et al. Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patient. BMC Gastroenterol. 2017;17(1):143.","journal-title":"BMC Gastroenterol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01368-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01368-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01368-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T23:02:03Z","timestamp":1768950123000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01368-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1368"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01368-9","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"30 November 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving humans were approved by the ethics committee of Shenzhen Second People's Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants\u2019 legal guardians\/next of kin. Written informed consent was obtained from the minor(s)\u2019 legal guardian\/next of kin for the publication of any potentially identifiable images or data included in this article. Written informed consent was obtained from the participant\/patient(s) for the publication of this case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics Statement"}},{"value":"The patient and his family members were fully engaged throughout the treatment and told us that his symptoms improved significantly after treatment and remained stable recently. The patient consented to the publication of this case report, and written informed consent was obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Patient Perspective"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"23"}}